Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping

Pharmacogenetics

Volumn 11, Issue 4, 2001, Pages 349-355

  Streetman, D S ^a   Kashuba, A D M ^a   Bertino J S , Jr ^a   Kulawy, R ^a   Rocci M L , Jr ^a   Nafziger, A N ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

CYP3A; Midazolam; Phenotyping; Urinary ratio

Indexed keywords

4 HYDROXYMIDAZOLAM; ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A; DRUG METABOLITE; FLUVOXAMINE; MIDAZOLAM; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CALCULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ADULT; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FEMALE; FLUVOXAMINE; HUMANS; LIVER; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; OXIDOREDUCTASES, N-DEMETHYLATING; PHENOTYPE;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0034974752     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200106000-00010     Document Type: Article

References (21)

1. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver
2. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily
3. Bimodal distribution of renal cytochrome P450 3A activity in humans
4. Excretion and metabolism of 14C-midazolam in humans following oral dosing
5. Debrisoquine hydroxylation capacity: Problems of assessment in two populations
6. Polymorphic drug oxidation: Pharmacokinetic basis and comparison of experimental indices
7. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations
8. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping
9. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam
10. Optimal plasma sampling to predict AUC of the CYP3A probe midazolam
11. Validation of a minimized plasma sampling strategy (MPSS) to calculate AUC of the CYP3A probe midazolam
12. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4
13. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs
14. The pharmacokinetics of midazolam in man
15. Phenotyping of drug-metabolizing enzymes in adults: A review of in-vivo cytochrome P450 phenotyping probes
16. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation
17. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients
18. Determination of drug-metabolizing enzyme activity in vivo: Pharmacokinetic and statistical issues
19. Midazolam is metabolized by at least three different cytochrome P450 enzymes
20. Identification of a polymorphically expressed member of the human cytochrome P-450III family
21. Studies on the expression of and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3)